Scynexis Inc (SCYX)

May 16, 2025

FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News

May 16, 2025

May 16, 2025

SCYNEXIS (NASDAQ:SCYX) Now Covered by Analysts at StockNews.com - Defense World

May 16, 2025

May 16, 2025

SCYNEXIS Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

May 16, 2025

Scynexis: Q1 Earnings Snapshot - CT Insider

May 16, 2025

May 15, 2025

SCYX Reports Strong Q1 Revenue, Progress in Clinical Trials | SC - GuruFocus

May 15, 2025

May 15, 2025

SCYX: Cash Reserves and Debt Repayment Update | SCYX Stock News - GuruFocus

May 15, 2025

May 15, 2025

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update | SCYX Stock News - GuruFocus

May 15, 2025

May 15, 2025

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 15, 2025

May 15, 2025

SCYNEXIS Antifungal Drug Cleared by FDA, but GSK Partnership Hits Major Roadblock - Stock Titan

May 15, 2025

May 15, 2025

SCYNEXIS INC SEC 10-Q Report - TradingView

May 15, 2025

May 12, 2025

News - Biostock

May 12, 2025

May 12, 2025

SCYNEXIS (SCYX) Projected to Post Earnings on Wednesday - Defense World

May 12, 2025

May 08, 2025

JPMorgan Chase & Co. Makes New Investment in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

May 08, 2025

May 02, 2025

SCYNEXIS, Inc. (NASDAQ:SCYX) Shares Sold by LPL Financial LLC - Defense World

May 02, 2025

May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025

May 01, 2025

StockNews.com Begins Coverage on SCYNEXIS (NASDAQ:SCYX) - Defense World

May 01, 2025

Apr 28, 2025

Aspergillosis Market Expected to Rise by 2034, Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, - Barchart.com

Apr 28, 2025

Apr 23, 2025

SCYNEXIS (NASDAQ:SCYX) Upgraded by StockNews.com to Hold Rating - Defense World

Apr 23, 2025

Apr 22, 2025

Blastomycosis Treatment Market Overall Study Report 2025-2032 | Janssen, Scynexis Inc, Novartis AG, Marck & Co. - openPR.com

Apr 22, 2025

Apr 10, 2025

Acute Vulvovaginal Candidiasis Treatment Market Poised - openPR.com

Apr 10, 2025

Apr 08, 2025

SCY-247 shows promise against resistant fungal infections By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

SCY-247 shows promise against resistant fungal infections - Investing.com

Apr 08, 2025

Apr 08, 2025

Breakthrough: SCYNEXIS's New Antifungal Drug Defeats 171 Resistant Fungal Strains in Latest Tests - Stock Titan

Apr 08, 2025

Apr 03, 2025

Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail

Apr 03, 2025

Mar 22, 2025

SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World

Mar 22, 2025

Mar 20, 2025

SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World

Mar 20, 2025

Mar 17, 2025

Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World

Mar 17, 2025

Mar 15, 2025

StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World

Mar 15, 2025

Mar 14, 2025

SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Mar 14, 2025

Mar 14, 2025

SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks

Mar 14, 2025

Mar 12, 2025

Scynexis Inc earnings beat by $0.06, revenue fell short of estimates - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 12, 2025

Mar 12, 2025

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart - Nasdaq

Mar 12, 2025

Mar 11, 2025

SCYX stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia

Mar 11, 2025

Mar 05, 2025

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound - BioSpace

Mar 05, 2025

Feb 26, 2025

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SCYNEXIS, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017SCYX - ACCESS Newswire

Feb 26, 2025

Feb 14, 2025

SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average – Time to Sell? - Defense World

Feb 14, 2025

Feb 02, 2025

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of SCYNEXIS, Inc. (SCYX) Investigation - ACCESS Newswire

Feb 02, 2025

Jan 21, 2025

SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World

Jan 21, 2025

Jan 12, 2025

Geode Capital Management LLC Acquires 36,405 Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jan 12, 2025

Jan 08, 2025

FEDERATED HERMES, INC. Reduces Stake in SCYNEXIS Inc: A Detailed Analysis - GuruFocus.com

Jan 08, 2025

Jan 06, 2025

Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail

Jan 06, 2025

Dec 30, 2024

SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update - Defense World

Dec 30, 2024

Dec 20, 2024

Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.

Dec 20, 2024